- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01964898
Post Acute Coronary Event Smoking Study (PACES)
Integrated Smoking Cessation and Mood Management for Cardiac Patients
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
The occurrence of Acute Coronary Syndrome (ACS; unstable angina, ST and non-ST elevation myocardial infarction) can be conceptualized as a "teachable moment," whereby patients may be more receptive to smoking cessation messages. Continued smoking following ACS is an independent predictor of mortality. Depressed mood post-ACS is also predictive of mortality, and smokers with depressed mood are less likely to abstain from smoking following an ACS hospitalization. Thus, a single, integrated treatment that targets both depressed mood and smoking could be highly effective in reducing post-ACS mortality. Behavioral Activation (BA) may be an ideal treatment for this population as BA can easily integrate both mood and smoking cessation related goals and it focuses on addressing restriction of valued activities, which is common in the post-ACS population.
Thus, the overall aim of the current study is test a BA treatment manual that integrates smoking cessation and mood management for post-ACS smokers (Behavioral Activation Treatment for cardiac patients who smoke; BAT-CS). We will conduct an RCT (N=72) comparing BAT-CS (1 in-hospital session and 5-9 post-discharge sessions) to Standard Care (SC; 1 in-hospital session and 5 mailed packets of printed self-help materials). Differences in smoking cessation, depressed mood, and positive affect will be compared between conditions.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Rhode Island
-
Providence, Rhode Island, Vereinigte Staaten, 02903
- The Miriam Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- ACS diagnosis documented in medical record
- smoked 3 or more cigarettes per day before being hospitalized
- between the ages of 18-75
- fluent in English
- regular access to a telephone
- lives in the Providence, RI area
- willing to "strongly consider" an attempt to quit smoking at discharge
Exclusion criteria:
- limited mental competency (i.e., Mini-Mental Status exam < 20)
- presence of current psychosis, serious mental illness, or suicidality, expectation that patient will not live through 6 month study period
- currently regularly attending counseling for depression or smoking cessation and plans to continue after discharge
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: BA for cardiac patients who smoke
Behavioral Activation Treatment for cardiac patients who smoke (BAT-CS).
Participant will receive (a) 1 hour of standard smoking cessation counseling in the hospital and (b) 5 to 9 Behavioral Activation (BA) counseling sessions focused on cessation and mood management after they leave the hospital.
BA sessions will occur over the 12 weeks after hospital discharge.
An 8 week supply of the nicotine patch will be provided if the patient is cleared by their MD.
|
5 to 9 Behavioral Activation (BA) counseling sessions focused on cessation and mood management.
BA sessions will occur over the 12 weeks after hospital discharge.
1 hour of in hospital counseling based on clinical guidelines
An 8 week supply of the nicotine patch will be provided if the patient is cleared by their MD.
|
Aktiver Komparator: Standard Care
Participant will receive (a) 1 hour of standard smoking cessation counseling in the hospital and (b) 5 packets of printed self-help materials for smoking cessation mailed 1, 3, 6, 9, and 12 weeks after hospital discharge.
An 8 week supply of the nicotine patch will be provided if the patient is cleared by their MD.
|
1 hour of in hospital counseling based on clinical guidelines
An 8 week supply of the nicotine patch will be provided if the patient is cleared by their MD.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Smoking Cessation: 7 Day Point Prevalence Abstinence
Zeitfenster: 6 months
|
No smoking, not even a puff, for 7 days; verified by carbon monoxide measurement.
Results are adjusted for nicotine patch use and concurrent medication treatment targeting cessation.
|
6 months
|
Continuous Abstinence From Smoking Since Discharge
Zeitfenster: 6 months
|
Results are adjusted for nicotine patch use and concurrent medication treatment targeting cessation.
|
6 months
|
Time to Smoking Relapse
Zeitfenster: 6 months
|
Time in days to first relapse (i.e., smoking on 7 consecutive days or smoking in 2 consecutive 7 day periods), which were determined through timeline follow back interviewing.
Results are adjusted for nicotine patch use and concurrent medication treatment targeting cessation.
|
6 months
|
Time to Smoking Lapse
Zeitfenster: 6 months
|
Time in days to first lapse (i.e., first puff of a cigarette) after discharge, which were determined through timeline follow back interviewing.
Results are adjusted for nicotine patch use and concurrent medication treatment targeting cessation.
|
6 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Depression: 9 Item Patient Health Questionnaire (PHQ-9)
Zeitfenster: Baseline to 6 months
|
The 9 item Patient Health Questionnaire (PHQ-9) ranges from 0-27 with higher scores indicating higher depression symptoms.
Adjusted for anti-depressant medication use and for cardiac rehabilitation attendance.
|
Baseline to 6 months
|
Depression: 10 Item Center for Epidemiologic Studies Depression Scale (CESD)
Zeitfenster: Baseline to 6 months
|
The 10 item Center for Epidemiologic Studies Depression Scale ranges from 0-30 with higher scores indicating higher depression symptoms.
Adjusted for anti-depressant medication use and for cardiac rehabilitation attendance.
|
Baseline to 6 months
|
Positive Affect
Zeitfenster: Baseline to 6 months
|
As measured by the 10 item Positive Affect Negative Affect Scales (PANAS).
The positive affect scale on the PANAS ranges from 5-25 with higher scores indicating greater positive affect in the past week.
Adjusted for anti-depressant medication use and for cardiac rehabilitation attendance
|
Baseline to 6 months
|
Negative Affect
Zeitfenster: Baseline to 6 months
|
As measured by the 10 item Positive Affect Negative Affect Scales (PANAS).
The negative affect scale on the PANAS ranges from 5-25 with higher scores indicating greater negative affect in the past week.
Adjusted for anti-depressant medication use and for cardiac rehabilitation attendance.
|
Baseline to 6 months
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Andrew M Busch, Ph.D, The Miriam Hospital Centers for Behavioral and Preventive Medicine
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Myokardischämie
- Herzkrankheiten
- Herz-Kreislauf-Erkrankungen
- Gefäßerkrankungen
- Akutes Koronar-Syndrom
- Physiologische Wirkungen von Arzneimitteln
- Neurotransmitter-Agenten
- Molekulare Mechanismen der pharmakologischen Wirkung
- Autonome Agenten
- Agenten des peripheren Nervensystems
- Cholinerge Wirkstoffe
- Ganglionäre Stimulanzien
- Nikotin-Agonisten
- Cholinerge Agonisten
- Nikotin
Andere Studien-ID-Nummern
- 5K23HL107391 (US NIH Stipendium/Vertrag)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Behavioral Activation (BA)
-
ElMindA LtdUnbekanntGesund | Kognitive Beeinträchtigung | Neurologische StörungVereinigte Staaten
-
Chinese University of Hong KongRekrutierung
-
Chinese University of Hong KongRekrutierung
-
Chinese University of Hong KongRekrutierung
-
BioNTech SEPfizerAbgeschlossenCOVID-19 | SARS-CoV-2-InfektionVereinigte Staaten
-
Providence VA Medical CenterAbgeschlossenDepression | DiabetesVereinigte Staaten
-
BioNTech SEPfizerZurückgezogen
-
Korea Health Industry Development InstituteRekrutierungParkinson KrankheitKorea, Republik von
-
University Rovira i VirgiliMinisterio de Economía y Competitividad, Spain; Obra Social de La CaixaAktiv, nicht rekrutierend
-
University of ExeterDevon Partnership NHS TrustAbgeschlossenBipolare DepressionVereinigtes Königreich